CN110607305A - 斑马鱼α7乙酰胆碱受体重组载体及重组细胞 - Google Patents
斑马鱼α7乙酰胆碱受体重组载体及重组细胞 Download PDFInfo
- Publication number
- CN110607305A CN110607305A CN201910815803.5A CN201910815803A CN110607305A CN 110607305 A CN110607305 A CN 110607305A CN 201910815803 A CN201910815803 A CN 201910815803A CN 110607305 A CN110607305 A CN 110607305A
- Authority
- CN
- China
- Prior art keywords
- alpha
- recombinant
- acetylcholine receptor
- zebra fish
- recombinant vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000252212 Danio rerio Species 0.000 title claims abstract description 38
- 239000013598 vector Substances 0.000 title claims abstract description 27
- 108010009685 Cholinergic Receptors Proteins 0.000 title claims abstract description 24
- 102000034337 acetylcholine receptors Human genes 0.000 title abstract description 12
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 abstract description 12
- 239000000556 agonist Substances 0.000 abstract description 8
- 238000012216 screening Methods 0.000 abstract description 3
- 239000005557 antagonist Substances 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 9
- 229960004373 acetylcholine Drugs 0.000 description 9
- 238000000246 agarose gel electrophoresis Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 108700000655 zebrafish chrna7 Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 210000000287 oocyte Anatomy 0.000 description 6
- 101150101112 7 gene Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 241000269368 Xenopus laevis Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 2
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种斑马鱼α7乙酰胆碱受体重组载体及重组细胞,属于基因工程技术领域。本发明公开的重组载体包括重组斑马鱼α7乙酰胆碱受体基因;重组细胞包括重组载体。本发明建立了斑马鱼α7乙酰胆碱受体的体外表达模型,为快速、高通量筛选作用于α7乙酰胆碱受体的专一激动剂和拮抗剂提供了良好的工具。
Description
技术领域
本发明涉及基因工程技术领域,更具体的说是涉及斑马鱼α7乙酰胆碱受体重组载体及重组细胞。
背景技术
乙酰胆碱受体(nAChRs)是自然界普遍存在的一种具有重要生理功能的膜蛋白,广泛分布于中枢神经系统,外周神经系统和免疫系统,能调节并影响生物体的一系列生理功能,如:痛觉、认识、记忆、焦虑等。已证实nAChRs是筛选诊断和治疗一大类重要基本药物的关键靶点,这些疾病包括成瘾、疼痛、癌症、帕金森、抑郁等。
α7 nAChR是其中重要的一种亚型,由五个α7亚基组成同型五聚体,其单个亚基结构可分为胞外结构域、胞内结构域和跨膜结构域三个部分。5个亚基连接环绕而成的跨膜结构域组成了离子通道,α7受体上有五个配体结合位点,可以通过与配体或者激动剂(拮抗剂)结合改变自身功能状态。α7 nAChR除了分布在一些神经系统以外,还存在于一些免疫系统的细胞,包括T细胞、B细胞和巨噬细胞等,参与多个神经生理和病理过程,包括神经保护,突触可塑性和神经元存活,胆碱能抗炎通路等,因此也是许多相关疾病和开放相关药物的重要靶点。目前新药的研发主要集中在α7 nAChR的激动剂上。通过激动α7 nAChR可以激活胆碱能抗炎通路(CAP),从而抑制炎性因子的释放,实现对多种组织抗炎镇痛的作用;另外,还可通过增强胆碱能系统的功能,抑制神经炎症达到治疗认知障碍的目的。
斑马鱼与高等脊椎动物在解剖学和生理学上具有高度同源性,具有高度相似的细胞结构、信号传导通路、器官解剖学以及认知行为、视觉、嗅觉、听觉、触觉等感官系统。与哺乳动物一样,斑马鱼也具有独立的器官和组织,包括脑和中枢神经系统、心脏和心血管系统、肾脏、具有代谢功能的肝脏、产生胰岛素的胰腺、储存脂肪的脂肪细胞、肠道、骨骼、肌肉、以及免疫和生殖系统。因此作为一种重要的模式生物,可广泛应用于疾病病理研究,药物药理和毒理学研究。
人们可以利用斑马鱼模型进行以α7 nAChR为靶点的相关药物研发。但是在众多的候选药物中,如何知道哪些药物能特异地作用于α7 nAChR,并筛选出来进行斑马鱼的药理学研究,这是一个需要解决的问题。如何快速、高效发现更多以α7 nAChR为靶点的活性物质,也将为今后靶向型药物的开发提供重要支撑。但目前缺乏可用于高效药物筛选的α7nAChR靶点体外模型。
因此,提供一种斑马鱼α7乙酰胆碱受体重组载体及重组细胞是本领域技术人员亟需解决的问题。
发明内容
有鉴于此,本发明提供了一种斑马鱼α7乙酰胆碱受体重组载体及重组细胞。
为了实现上述目的,本发明采用如下技术方案:
一种重组斑马鱼α7乙酰胆碱受体基因,其核苷酸序列如SEQ ID NO.4所示。
进一步,所述重组斑马鱼α7乙酰胆碱受体基因,在斑马鱼α7乙酰胆碱受体基因两端加入人工接头和酶切位点;所述斑马鱼α7乙酰胆碱受体基因的核苷酸序列如SEQ IDNO.1所示。
进一步,一种重组载体,包括所述重组斑马鱼α7乙酰胆碱受体基因。
进一步,一种重组载体的构建方法,以细菌表达载体pBluescript SK(-)为骨架载体,将重组斑马鱼α7乙酰胆碱受体基因插入T7启动子下游,获得重组载体。
进一步,一种重组细胞,包括所述重组载体。
经由上述的技术方案可知,与现有技术相比,本发明公开提供了一种斑马鱼α7乙酰胆碱受体重组载体及重组细胞,重组载体的构建方法,为将包含zα7基因编码序列的核苷酸片段插入原始载体pBluescript SK(-)中,zα7基因位于pBluescript SK(-)中的HindIII和Xba I两个限制性内切酶位点之间;插入的核苷酸片段SEQ ID NO.4序列保留zα7基因自身的终止密码子,并能进行体外转录,在体外爪蟾卵母细胞的细胞膜表面表达出有活性的zα7 nAChR;该受体为体外高效、快速筛选作用于zα7 nAChR的活性物质以及研究他们与受体相互作用的分子机制奠定了基础。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据提供的附图获得其他的附图。
图1附图为本发明提取的斑马鱼肝脏组织RNA琼脂糖凝胶电泳图;
其中,M:核酸Marker DL2000;L1:Liver,斑马鱼肝脏RNA;
图2附图为本发明斑马鱼肝脏组织cDNA琼脂糖凝胶电泳图;
其中,M:核酸Marker DL2000;L1:Liver,斑马鱼肝脏cDNA;
图3附图为本发明斑马鱼zα7基因PCR琼脂糖凝胶电泳图;
其中,M:核酸Marker DL2000;1:PCR扩增斑马鱼zα7基因;
图4附图为本发明表达载体pBluescript SK(-)的图谱;
图5附图为本发明包含斑马鱼α7 nAChR(zα7)基因的重组载体图谱;
图6附图为本发明重组载体质粒和SalⅠ单酶切后的重组质粒琼脂糖凝胶电泳图;
其中,M1:核酸Marker DL10000;D1:重组载体质粒;D2:Sal Ⅰ单酶切重组质粒后线性化模板;M2:核酸MarkerDL2000;
图7附图为本发明体外转录获得斑马鱼α7 nAChR(zα7)基因RNA琼脂糖凝胶电泳图;
其中,M:核酸Marker RL6000;1:体外转录获得斑马鱼α7 nAChR(zα7)基因RNA;
图8附图为本发明电生理检测斑马鱼α7 nAChR模型电流图;
图9附图为本发明斑马鱼α7 nAChR模型针对激动剂ACh的半数有效剂量(EC50)。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1斑马鱼组织RNA的提取
选取体长3-5厘米的健康成年斑马鱼,取其肝脏组织,液氮中快速冷冻,利用RNA提取试剂盒(南京诺唯赞生物科技有限公司)提取斑马鱼肝脏组织的RNA。提取步骤参考说明书,提取过程中全程戴口罩和手套,在RNA间的超净工作台操作,操作过程小心RNase的污染,防止RNA降解。将得到的肝脏组织总RNA分别利用1%琼脂糖凝胶电泳检测(图1)和紫外分光光度计测其浓度和纯度,其浓度为491.6ng/μl,A260/A280为2.08,纯度较好。
实施例2斑马鱼cDNA的获取
以提取的斑马鱼肝脏组织的总RNA为模板,体外进行反转录,利用cDNA反转录试剂盒(Thermo Fisher Scientific,High-Capacity cDNA Reverse Transcription Kits),反应体系如下(总体积20μl):
试剂 | 体积(μl) |
10×RT Buffer | 2 |
25×dNTP Mix(100mM) | 0.8 |
10×RT Random Primers | 2 |
MultiScribe Reverse Transcriptase | 1 |
RNAse Inhibitor | 1 |
Nuclease-free H<sub>2</sub>O | 3.2 |
Total RNA | 10 |
反应条件:
反应步骤 | 温度℃ | 时间(min) |
1 | 25 | 10 |
2 | 37 | 120 |
3 | 85 | 5 |
4 | 4 | ∞ |
对反转录获得的cDNA进行琼脂糖凝胶电泳检测,结果如图2所示。
实施例3斑马鱼α7 nAChR基因克隆
根据斑马鱼α7 nAChR(zα7)基因序列(SEQ ID NO.1)设计引物P1、P2,以实施例2获得的cDNA为模板,进行PCR扩增。
其中,P1、P2的引物序列如下:
P1:5’-ATTCACTTCTGCCCGTGGGATGC-3’;SEQ ID NO.2;
P2:5’-GTGCAAAAGCCATACATACTGTG-3’;SEQ ID NO.3;
PCR反应体系:Mix,25μl;ddH2O,19μl;P1,2μl;P2,2μl;cDNA,2μl;总体积为50μl。
PCR反应条件:94℃,5min;94℃ 30s,50℃ 30s,72℃ 90s,30个循环;72℃,10min。并使用1%琼脂糖凝胶电泳检测PCR反应产物,结果如图3所示。
实施例4构建zα7重组载体
实施例3扩增纯化后的PCR产物,通过化学合成在PCR产物(核苷酸序列为SEQ IDNO.1)两端加入人工接头,引入限制性内切酶粘性末端(核苷酸序列为SEQ ID NO.4),粘性末端分别为限制性内切酶HindIII/XbaI,将表达载体pBluescript SK(-)(图4)进行双酶切,然后与核苷酸片段(SEQ ID NO.4)进行连接,构建zα7重组载体(图5)。
其中,人工接头和HindIII(AAGCTT)粘性末端序列为:
5’-AAGCTTGATATCGAATTCGGGCCGTGCTGCCGCTCCAGCGAC-3’;SEQ ID NO.5;
人工接头和XbaI(TCTAGA)粘性末端序列为:
5’-CCGAATTCCTGCAGCCCGGGGGATCCACTAGTTCTAGA-3’;SEQ ID NO.6;
将构建好的zα7重组载体利用氯化钙化学转化法转入大肠杆菌DH5α,形成重组菌株,重组菌株培养后,提取zα7重组质粒。通过测序,确定插入基因导入宿主后未发生突变。
实施例5线性化模板的制备和cappedRNA(cRNA)的获取
对zα7重组质粒进行单酶切,以获得体外转录的线性化模板。酶切反应体系100μl,反应体系如下:zα7重组质粒10μl(~5μg),5μl限制性内切酶SalⅠ,10μl 10×H buffer,其余均为无菌双蒸水;37℃,反应2h;进行琼脂糖凝胶电泳检测,结果如图6所示。
以T7为启动子,酶切线性化的质粒作为体外转录的模板;体外转录反应体系20μl,反应体系如下:以酶切完全的zα7重组质粒作为体外转录的模板,线性化模板4μl(~1μg),2μl的10×反应缓冲液,10μl的2×NTP/CAP(T7),2μl的Enzyme Mix,2μl的灭菌双蒸水;37℃,反应1h。对体外转录后得到的RNA(图7)进行纯化,可以用于后序受体的表达。
实施例6zα7 nAChR的表达和检测
利用雌性非洲爪蟾(购置于美国Nasco公司,实验室饲养两个月以上),将爪蟾冰浴麻醉后,手术取爪蟾卵母细胞。利用该卵母细胞表达zα7 nAChR。将zα7 nAChR的RNA通过显微注射,注入爪蟾卵母细胞;注射后的卵母细胞17℃培养2-5天,检测受体的表达情况。zα7乙酰胆碱受体表达于细胞膜表面,利用激动剂乙酰胆碱检测受体活性,受体在激动剂诱导下产生内向电流。
双电极电压钳检测zα7受体的表达情况。实验条件如下:钳制电压-70mV,采集频率100HZ,滤波10HZ。每分钟的记录时间内,给予2s乙酰胆碱(ACh)刺激。每个循环重复3次。记录产生的电流情况(图8)。结果表明,在激动剂ACh的刺激下,成功表达zα7 nAChR的爪蟾卵母细胞,其细胞膜表面的zα7nAChR通道开放,产生离子流动,该电流可以被双电极电压钳仪器记录到,显示为一个内向电流。不同浓度的ACh可以诱导产生不同大小的电流。
根据不同浓度ACh诱导产生电流大小不同,计算zα7 nAChR对ACh的半数有效最大浓度(half maximal effective concentration,EC50),结果见图9,EC50=222.7μM。EC50表示zα7受体针对激动剂ACh能引起50%最大效应的浓度。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
序列表
<110> 海南大学
<120> 斑马鱼α7乙酰胆碱受体重组载体及重组细胞
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1716
<212> DNA
<213> Artificial Sequence
<400> 1
attcacttct gcccgtggga tgctgagaga gactcttcat aacaccaaga cctatatcac 60
cacaccagct tttctattaa tttctgcaat ttaatctaaa taggaagatg ggaatttggg 120
aatatactct ttatttcacc accacatgct gcctatggag tgtgtcactt cagggggagc 180
atcagaggag actctataga gacctgatga aagattataa cccactggag agacctgtgt 240
tcaatgacac ccactcactc acggtgtatt tcagcatgag cctcatgcag attatggatg 300
tggatgaaaa gaatcaagtt cttacgacca acatttggct acagctgtac tggtatgact 360
actatcttca atggaacgcc tcagaatatc ctggagtaac caatgtaagg tttcctgaca 420
gtcagatctg gaagcctgac atcttacttt ataacagtgc tgatgaaagg tttgatgcca 480
catttcatac taatgtgctg gtgaactctt ctggtgcctg ccaatactta ccgccaggga 540
tcttcaaaag cacctgctac atcgacgttc gctggttccc ctttgatctt cagaggtgtg 600
atctgaaatt tggctcctgg acgtatggag gatggtctct ggacctgcag atgattgatg 660
ccgacatcac aggatacatt gctaatggag agtgggacct tgtggaagtt ccaggtagac 720
ggaatgagag gttctacgac tgctgcaagg agccgtaccc agatgtgact tttacggtgg 780
tgatgcggag acgaacactg tattacggtc ttaatctact tattccctgt gtgctcatct 840
ctactctggc cctgctggtg ttcctgctgc ctgctgactc aggagaaaag atctcgctcg 900
ggatcaccgt cctgctctcg ctgacagttt tcatgctttt ggtagcagag ataatgccgg 960
caacatctga ctctgtgcct ttaatagctc agtattttgc caccaccatg gttattgttg 1020
gactatctgt aatagccaca gtctgggttt tacaatacca ctaccatgat cctgaaggag 1080
gaaaaatgcc aaaatggaca cgtgtggtgc tgttgaactg gtgtgcctgg ttcctgcgga 1140
tgaagagacc tggcgaagac aaagttcgcc cagcttgtca caacaagcag ccgcgcagca 1200
gcctctccag cgtggatcta aacatcagcc ctggagtcgc acagtccacc aatggaaacc 1260
tgctgtacat cggcttccgc gggatggaca ctattcacta tgctacttca cccgattctg 1320
gggtgatctg cagccggctt gtggcgaccg gagaggagga tgtgctgctc cccggagccc 1380
aggcatcttc agtcagtagt agcggccctg gagaaaccga actgtccaag atcttggatg 1440
aggtgcggta catttccaag cgctttcggg accaagacga ggaagacact gtgtgtaatg 1500
agtggaagtt tgcagcgtct gtgattgacc gtctctgtct catggctttt tccctgttca 1560
ccatcctctg caccattggt atcttaatgt ctgcccctaa ctttgttgag gccatatcaa 1620
aagatttttt cacctgaagc cttcacttac ccttatattg tagctatatc tacttctcag 1680
agtctcctaa aggcacagta tgtatggctt ttgcac 1716
<210> 2
<211> 23
<212> DNA
<213> Artificial Sequence
<400> 2
attcacttct gcccgtggga tgc 23
<210> 3
<211> 23
<212> DNA
<213> Artificial Sequence
<400> 3
gtgcaaaagc catacatact gtg 23
<210> 4
<211> 1796
<212> DNA
<213> Artificial Sequence
<400> 4
aagcttgata tcgaattcgg gccgtgctgc cgctccagcg acattcactt ctgcccgtgg 60
gatgctgaga gagactcttc ataacaccaa gacctatatc accacaccag cttttctatt 120
aatttctgca atttaatcta aataggaaga tgggaatttg ggaatatact ctttatttca 180
ccaccacatg ctgcctatgg agtgtgtcac ttcaggggga gcatcagagg agactctata 240
gagacctgat gaaagattat aacccactgg agagacctgt gttcaatgac acccactcac 300
tcacggtgta tttcagcatg agcctcatgc agattatgga tgtggatgaa aagaatcaag 360
ttcttacgac caacatttgg ctacagctgt actggtatga ctactatctt caatggaacg 420
cctcagaata tcctggagta accaatgtaa ggtttcctga cagtcagatc tggaagcctg 480
acatcttact ttataacagt gctgatgaaa ggtttgatgc cacatttcat actaatgtgc 540
tggtgaactc ttctggtgcc tgccaatact taccgccagg gatcttcaaa agcacctgct 600
acatcgacgt tcgctggttc ccctttgatc ttcagaggtg tgatctgaaa tttggctcct 660
ggacgtatgg aggatggtct ctggacctgc agatgattga tgccgacatc acaggataca 720
ttgctaatgg agagtgggac cttgtggaag ttccaggtag acggaatgag aggttctacg 780
actgctgcaa ggagccgtac ccagatgtga cttttacggt ggtgatgcgg agacgaacac 840
tgtattacgg tcttaatcta cttattccct gtgtgctcat ctctactctg gccctgctgg 900
tgttcctgct gcctgctgac tcaggagaaa agatctcgct cgggatcacc gtcctgctct 960
cgctgacagt tttcatgctt ttggtagcag agataatgcc ggcaacatct gactctgtgc 1020
ctttaatagc tcagtatttt gccaccacca tggttattgt tggactatct gtaatagcca 1080
cagtctgggt tttacaatac cactaccatg atcctgaagg aggaaaaatg ccaaaatgga 1140
cacgtgtggt gctgttgaac tggtgtgcct ggttcctgcg gatgaagaga cctggcgaag 1200
acaaagttcg cccagcttgt cacaacaagc agccgcgcag cagcctctcc agcgtggatc 1260
taaacatcag ccctggagtc gcacagtcca ccaatggaaa cctgctgtac atcggcttcc 1320
gcgggatgga cactattcac tatgctactt cacccgattc tggggtgatc tgcagccggc 1380
ttgtggcgac cggagaggag gatgtgctgc tccccggagc ccaggcatct tcagtcagta 1440
gtagcggccc tggagaaacc gaactgtcca agatcttgga tgaggtgcgg tacatttcca 1500
agcgctttcg ggaccaagac gaggaagaca ctgtgtgtaa tgagtggaag tttgcagcgt 1560
ctgtgattga ccgtctctgt ctcatggctt tttccctgtt caccatcctc tgcaccattg 1620
gtatcttaat gtctgcccct aactttgttg aggccatatc aaaagatttt ttcacctgaa 1680
gccttcactt acccttatat tgtagctata tctacttctc agagtctcct aaaggcacag 1740
tatgtatggc ttttgcaccc gaattcctgc agcccggggg atccactagt tctaga 1796
<210> 5
<211> 42
<212> DNA
<213> Artificial Sequence
<400> 5
aagcttgata tcgaattcgg gccgtgctgc cgctccagcg ac 42
<210> 6
<211> 38
<212> DNA
<213> Artificial Sequence
<400> 6
ccgaattcct gcagcccggg ggatccacta gttctaga 38
Claims (5)
1.一种重组斑马鱼α7乙酰胆碱受体基因,其特征在于,其核苷酸序列如SEQ ID NO.4所示。
2.根据权利要求1所述的一种重组斑马鱼α7乙酰胆碱受体基因,其特征在于,在斑马鱼α7乙酰胆碱受体基因两端加入人工接头和酶切位点;所述斑马鱼α7乙酰胆碱受体基因的核苷酸序列如SEQ ID NO.1所示。
3.一种重组载体,其特征在于,所述重组载体包括所述重组斑马鱼α7乙酰胆碱受体基因。
4.根据权利要求1所述的一种重组载体的构建方法,其特征在于,以细菌表达载体pBluescript SK(-)为骨架载体,将重组斑马鱼α7乙酰胆碱受体基因插入T7启动子下游,获得重组载体。
5.一种重组细胞,其特征在于,包括所述重组载体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910815803.5A CN110607305A (zh) | 2019-08-30 | 2019-08-30 | 斑马鱼α7乙酰胆碱受体重组载体及重组细胞 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910815803.5A CN110607305A (zh) | 2019-08-30 | 2019-08-30 | 斑马鱼α7乙酰胆碱受体重组载体及重组细胞 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110607305A true CN110607305A (zh) | 2019-12-24 |
Family
ID=68891052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910815803.5A Pending CN110607305A (zh) | 2019-08-30 | 2019-08-30 | 斑马鱼α7乙酰胆碱受体重组载体及重组细胞 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110607305A (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050170360A1 (en) * | 2004-01-30 | 2005-08-04 | Papke Roger L. | Variant neuronal nicotinic alpha-7 receptor and methods of use |
US20060057614A1 (en) * | 2004-08-04 | 2006-03-16 | Nathaniel Heintz | Tethering neuropeptides and toxins for modulation of ion channels and receptors |
CN1788091A (zh) * | 2002-09-27 | 2006-06-14 | Dsmip资产公司 | 通过法夫酵母生产角黄素 |
US20060142188A1 (en) * | 2003-02-14 | 2006-06-29 | Memory Pharmaceuticals Corporation | Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof |
WO2006091672A2 (en) * | 2005-02-23 | 2006-08-31 | Dow Agrosciences Llc | Novel assays utilizing nicotinic acetylcholine receptor subunits |
TW200636242A (en) * | 2004-12-23 | 2006-10-16 | Pfizer Prod Inc | Methods of modulating the activities of α7 nicotinic acetylcholine receptor |
CN1938422A (zh) * | 2004-04-08 | 2007-03-28 | 金克克国际有限公司 | 突变体α-淀粉酶 |
CN103483439A (zh) * | 2012-06-15 | 2014-01-01 | 海南大学 | αO-超家族芋螺毒素肽、其药物组合物及用途 |
CN107164405A (zh) * | 2017-05-24 | 2017-09-15 | 中国环境科学研究院 | 用转基因斑马鱼检测具乙酰胆碱酯酶抑制活性物质的方法 |
CN109825513A (zh) * | 2019-04-10 | 2019-05-31 | 吉林农业大学 | 大豆病程相关蛋白基因、重组载体、重组细胞、重组体系及应用 |
-
2019
- 2019-08-30 CN CN201910815803.5A patent/CN110607305A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1788091A (zh) * | 2002-09-27 | 2006-06-14 | Dsmip资产公司 | 通过法夫酵母生产角黄素 |
US20060142188A1 (en) * | 2003-02-14 | 2006-06-29 | Memory Pharmaceuticals Corporation | Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof |
US20050170360A1 (en) * | 2004-01-30 | 2005-08-04 | Papke Roger L. | Variant neuronal nicotinic alpha-7 receptor and methods of use |
CN1938422A (zh) * | 2004-04-08 | 2007-03-28 | 金克克国际有限公司 | 突变体α-淀粉酶 |
US20060057614A1 (en) * | 2004-08-04 | 2006-03-16 | Nathaniel Heintz | Tethering neuropeptides and toxins for modulation of ion channels and receptors |
TW200636242A (en) * | 2004-12-23 | 2006-10-16 | Pfizer Prod Inc | Methods of modulating the activities of α7 nicotinic acetylcholine receptor |
WO2006091672A2 (en) * | 2005-02-23 | 2006-08-31 | Dow Agrosciences Llc | Novel assays utilizing nicotinic acetylcholine receptor subunits |
CN101180543A (zh) * | 2005-02-23 | 2008-05-14 | 美国陶氏益农公司 | 使用烟碱乙酰胆碱受体亚单位的新检测方法 |
CN103483439A (zh) * | 2012-06-15 | 2014-01-01 | 海南大学 | αO-超家族芋螺毒素肽、其药物组合物及用途 |
CN107164405A (zh) * | 2017-05-24 | 2017-09-15 | 中国环境科学研究院 | 用转基因斑马鱼检测具乙酰胆碱酯酶抑制活性物质的方法 |
CN109825513A (zh) * | 2019-04-10 | 2019-05-31 | 吉林农业大学 | 大豆病程相关蛋白基因、重组载体、重组细胞、重组体系及应用 |
Non-Patent Citations (12)
Title |
---|
GHOSH R等: "Overexpression of outer membrane porins in E. coli using pBluescript-derived vectors", 《GENE EXPR》 * |
HUANG V等: "Danio rerio cholinergic receptor, nicotinic, alpha 7 (neuronal) (chrnα7), mRNA", 《NCBI GENBANK DATABASE》 * |
NCBI GENBANK DATABASE: "rpigca0_007330.y1 clu Sus scrofa cDNA 5", mRNA sequence", 《NCBI GENBANK DATABASE》 * |
SEPICH DS等: "Autonomous expression of the nic1 acetylcholine receptor mutation in zebrafish muscle cells", 《DEV BIOL》 * |
于津鹏等: "α7乙酰胆碱受体在非洲爪蟾卵母细胞上的表达", 《第十一届中国生物毒素研究及医药应用年会论文集》 * |
于海鹏等: "乙酰胆碱受体α4β2亚型在非洲爪蟾卵母细胞中的表达", 《生物技术通报》 * |
卢家红等: "α7 cDNA真核表达载体的构建及其在H4细胞中的表达", 《复旦学报(医学版)》 * |
彭博等: "朱砂叶螨乙酰胆碱酯酶的原核表达及其活性分析", 《应用与环境生物学报》 * |
朱晓鹏等: "α7烟碱型乙酰胆碱受体点突变体的制备及其功能研究", 《中国海洋药物》 * |
林烨: "乙酰胆碱受体的重组表达以及抗AChR抗体检测方法的建立", 《中国学位论文全文数据库》 * |
王彬彬: "突变对家蚕1型乙酰胆碱酯酶基因结构及功能的影响研究", 《中国学位论文全文数据库》 * |
罗素兰等: "特异阻断神经型α7乙酰胆碱受体的海南产天然芋螺毒素筛选", 《第九届中国生物毒素学术研讨会论文》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | A novel microRNA-124/PTPN1 signal pathway mediates synaptic and memory deficits in Alzheimer’s disease | |
EP3389725B1 (en) | Compositions and methods for treatment of central nervous system diseases | |
US9617535B2 (en) | Oligonucleotide complex compositions and methods of use as gene alteration tools | |
Zhou et al. | Programmable base editing of the sheep genome revealed no genome-wide off-target mutations | |
Nakajima et al. | Thyroid hormone receptor α–and β–knockout Xenopus tropicalis tadpoles reveal subtype-specific roles during development | |
CN109207524A (zh) | 基于fto基因的人类肥胖症斑马鱼模型的建立与应用 | |
CN102051380B (zh) | 一种心律失常动物模型建立的方法 | |
CN109929875B (zh) | 一种lag3基因人源化动物模型的构建方法及其应用 | |
CN110862988B (zh) | 一种sgRNA及其构建的CREBRF点突变型巴马香猪和应用 | |
Romanowski et al. | Interleukin-17 gene polymorphisms in patients with post-transplant diabetes mellitus | |
CN110607305A (zh) | 斑马鱼α7乙酰胆碱受体重组载体及重组细胞 | |
US9522978B2 (en) | PI polyamide | |
Zhu et al. | Cloning and characterization of the LEF/TCF gene family in grass carp (Ctenopharyngodon idella) and their expression profiles in response to grass carp reovirus infection | |
Deprá et al. | The hobo transposon and hobo-related elements are expressed as developmental genes in Drosophila | |
CN114426960B (zh) | 一种PDA@CRISPR/Cas9/sgHMGA2 NPs复合体、制备方法及应用 | |
CN108823300A (zh) | circRNA在制备诊断骨关节炎的产品上的应用 | |
Bonaldo et al. | 1274 full-open reading frames of transcripts expressed in the developing mouse nervous system | |
CN110904046B (zh) | Islr基因在制备治疗肥胖及改善胰岛素抵抗的药物中的应用 | |
Vandepoele et al. | The NBPF1 promoter has been recruited from the unrelated EVI5 gene before simian radiation | |
Eisenschenk et al. | The expression of histamine H4 receptor mRNA in the skin and other tissues of normal dogs | |
CN110511933A (zh) | 一种大鼠长链非编码lncRNA-lncMSTRG10078及其抵抗细胞损伤的应用 | |
McNeer et al. | Correction of F508del CFTR in airway epithelium using nanoparticles delivering triplex-forming PNAs | |
CN110951735B (zh) | 一种长链非编码RNA lnc-PMIF及其小干扰RNA和应用 | |
Al-Obaide et al. | Novel enhancer mediates the RPL36A-HNRNPH2 readthrough loci and GLA gene expressions associated with fabry disease | |
JP2005500835A5 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191224 |